TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc., filing under ticker MTAC, submitted an 8-K current report with the SEC on July 24, 2025. The company reached the public markets through a business combination with MedTech Acquisition Corp, a healthcare-focused blank-check vehicle that completed its IPO in 2021 and was sponsored by MedTech Acquisition Sponsor, LLC. Operating in the medical technology and oncology sector, TriSalus develops pressure-enabled regional drug delivery systems aimed at treating liver and pancreatic cancers, with its lead platform the TriNav Infusion System. The July 2025 8-K represents a post-merger current report filed under the company's ongoing SEC disclosure obligations. Sign up at SpacDesk for full filing history, deal timelines, and sponsor data on TriSalus and hundreds of other SPAC transactions.